OPEN DISCUSSION ON PIPELINES OF EXPERIMENTAL TREATMENTS FOR ASTHMA, ALLERGY/RHINITIS, COPD, MULTIMORBIDITY: PANEL DISCUSSION OF RD DIRECTORS OF THE MAIN RESPIRATORY PHARMA INDUSTRIES
Conductors Leonardo M. Fabbri, Pierluigi Paggiaro, Alberto Papi and Giovanni Passalacqua

Introduzione

 

Mark Parry-Billings
Head of Corporate Drug Development
Chiesi Farmaceutici

 

Carmen Stabile
Respiratory Medical Lead
GlaxoSmithKline Spa – Pharmaceuticals

 

Andrea Rizzi
Medical Director Respiratory & Allergy and Diabetes
Ilaria Barisone
Clinical Research Medical Advisor
Novartis Italia

 

Devis Moretti
Medical Lead Immunology
Sanofi Genzyme

 

Berta Juliá de Páramo
Regional Director Medical Affairs (EUCAN)
Respiratory, MSD

 

Najy Alsayed
Global Therapeutic Area Head – Infectious Diseases
Menarini Group

 

Rita De Santis
Head Biotechnology Research and Development
Alfasigma

 

Maria Belvisi
SVP Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D
AstraZeneca

 

Discussione

 

Introduzione

 

Bartolome Celli
READY FOR A NEW DEFINITION OF COPD?

      Comunicato stampa

 

Discussione

 

Alvar Agusti
A NEW UNDERSTANDING OF COPD BEYOND SMOKING

 

Discussione

 

Eugenio Baraldi
EARLY EXPOSURE/EVENTS RESPONSIBLE FOR FUTURE DEVELOPMENT OF COPD?

 

Discussione

 

Stefano Gasparini
NOVEL DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC APPROACHES

 

Discussione

 

Introduzione

 

Helen K. Reddel
PRN ICS/FORMOTEROL VERSUS REGULAR LABA/ICS WITH SABA PRN IN ASTHMA

 

Discussione

 

Guy Brusselle
MANAGEMENT OF UNCONTROLLED SEVERE ASTHMA WITH THE NEW BIOLOGICS

 

Discussione

 

GROUP DISCUSSION: BREAKING NEWS IN GINA

      

Introduzione

 

Jean Bousquet

 

GROUP DISCUSSION: BREAKING NEWS IN ARIA

 

      

Pierluigi Paggiaro

 

Alberto Papi

 

Raffaele F. Antonelli Incalzi

 

Fernando D. Martinez

 

Marco Contoli

 

Erik Melén